NCT03155620 2026-02-10Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting1,376 enrolled
NCT04917042 2026-02-04Tazemetostat in Malignant Peripheral Nerve Sheath TumorsUniversity of FloridaPhase 2 Active not recruiting10 enrolled 12 charts
NCT05407441 2025-10-03Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsDana-Farber Cancer InstitutePhase 1/2 Recruiting49 enrolled
NCT02601950 2025-06-22A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaIpsenPhase 2 Completed267 enrolled 25 charts 2 FDA